Sellas

SLS NASDAQ
0.5804
-0.1997
-25.60%
After Hours: 0.6050 +0.0246 +4.24% 17:15 05/24 EDT
Open
0.6600
Prev Close
0.7801
High
0.7013
Low
0.5800
Volume
1.55M
Avg Vol (3M)
346.34K
52 Week High
6.97
52 Week Low
0.5800
% Turnover
6.17%
Market Cap
14.61M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Sellas SLS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
MORE >

Recently

Name
Price
%Change